Related Experiment Video
Updated: Nov 18, 2025
Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model
Published on: September 20, 2020
The Effect of 3-Month Growth Hormone Administration and 12-Month Follow-Up Duration among Heart Failure Patients Four
Afshin Amirpour1, Mehrbod Vakhshoori2, Reihaneh Zavar1
1Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Insights
Growth hormone (GH) improved left ventricular ejection fraction (LVEF) in heart failure (HF) patients. However, benefits diminished after treatment cessation, necessitating further research for sustained cardiac function improvement.
Area of Science:
- Cardiology
- Endocrinology
- Clinical Trials
Background:
- The therapeutic potential of growth hormone (GH) in heart failure (HF) remains underexplored.
- Investigating GH's impact on cardiac function in HF patients post-myocardial infarction (MI) is crucial.
Purpose of the Study:
- To evaluate the effect of a 3-month GH prescription on cardiac parameters in Iranian HF patients.
- Key parameters assessed include left ventricular ejection fraction (LVEF), ventricular dimensions, and pulmonary arterial pressure (PAP).
Main Methods:
- A pilot randomized, double-blind study involving 16 clinically stable HF patients with LVEF < 40%.
- Participants received either 5 IU subcutaneous GH or placebo every other day for 3 months.
- Cardiac outcomes were evaluated post-intervention and at a 9-month follow-up.
Main Results:
- GH administration significantly increased LVEF from baseline at 3 months (32% to 43.8%).
- LVEF declined post-treatment cessation, returning to near baseline levels after 9 months.
- GH group showed significantly higher LVEF and lower end-systolic diameter (ESD) compared to placebo at treatment end.
Conclusions:
- GH treatment in HF patients is associated with improved LVEF.
- The observed cardiac benefits were not sustained after GH cessation.
- Further randomized clinical trials are required to confirm these findings and explore long-term efficacy.
Background:
The probable impact of growth hormone (GH) as a heart failure (HF) treatment strategy is still less investigated. Therefore, we aimed to evaluate the relation of 3-month GH prescription on left ventricular ejection fraction (LVEF), interventricular septum (IVS), posterior left ventricle (LV) thickness, end systolic and end diastolic diameters (ESD and EDD), and pulmonary arterial pressure (PAP) among Iranian individuals suffering from HF due to MI attack.
Methods:
A total of 16 clinically stable participants with HF diagnosis and LVEF < 40% were selected for enrollment in this pilot randomized double-blinded study. They were randomly assigned equally to groups received 5 IU subcutaneous GH or placebo. Injections were done every other day for a total of 3-month duration. After termination of intervention and nine months afterwards, cardiac outcomes were assessed.
Results:
Baseline and 12-month posttrial participants' characteristics were similar. LVEF was increased significantly by three months started from baseline in individuals receiving GH (32 ± 3.80% to 43.80 ± 4.60%, P = 0.002). During the next 9 months of follow-up concurrent with cessation of injections, LVEF was declined (43.80 ± 4.60% to 32.20 ± 6.97%, P = 0.008). LVEF and ESD were remarkably higher and lower in GH group compared with controls by the end date of injections (43.80 ± 4.60% vs. 33.14 ± 4.84%, P = 0.02 and 39.43 ± 3.45 mm vs. 33 ± 3.16 mm, P = 0.03, respectively). No other considerable association was found in terms of other predefined variables in neither GH nor placebo groups.
Conclusions:
GH administration in HF patients was associated with increased LVEF function. Several randomized clinical trials are necessary proving this relation. This trial is registered with IRCT201704083035N1.
More Related Videos
11:51Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
Published on: March 1, 2016
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:30Heart Failure V: Medical Management
01:26Heart Failure III: Clinical Manifestations
01:29Heart Failure II: Pathophysiology
01:26Heart Failure Drugs: Inotropic Agents
01:14Myocarditis III: Medical Management